Erudio Healtherudio.com
Drug
Lenvatinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying lenvatinib: LITESPARK-011. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 29 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LITESPARK-011 NCT04586231 · Merck Sharp & Dohme LLC | advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy | Phase 3 | 1,422 | 235 | Deep | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| EMERALD-3 NCT05301842 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| LEAP-012 NCT04246177 · Merck Sharp & Dohme LLC DeepView → | incurable non-metastatic hepatocellular carcinoma | Phase 3 | Deep | View | |||
| CheckMate 9DW NCT04039607 · Bristol-Myers Squibb DeepView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| LITESPARK-012 NCT04736706 · Merck Sharp & Dohme LLC DeepView → | first-line advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-775 NCT03517449 · Eisai Inc. DeepView → | previously treated advanced endometrial cancer | Phase 3 | Deep | View | |||
| LEAP-002 NCT03713593 · Merck Sharp & Dohme LLC DeepView → | first-line advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| CARE1 NCT06364631 · Gustave Roussy, Cancer Campus, Grand Paris DeepView → | first-line metastatic renal cell carcinoma | Phase 3 | Deep | View | |||
| IMbrave251 NCT04770896 · Hoffmann-La Roche DeepView → | hepatocellular carcinoma previously treated with atezolizumab and bevacizumab | Phase 3 | Deep | View | |||
| BioFront NCT07383441 · SWOG Cancer Research Network DeepView → | advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| PECATI NCT04710628 · MedSIR DeepView → | pretreated metastatic B3 thymoma and thymic carcinoma | Phase 2 | Deep | View | |||
| LEAP-011 NCT03898180 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| LEAP-015 NCT04662710 · Merck Sharp & Dohme LLC DeepView → | first-line advanced/metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-365 NCT02861573 · Merck Sharp & Dohme LLC DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| KEYNOTE-146 NCT02501096 · Eisai Inc. StandardView → | advanced solid tumors | Phase 1/Phase 2 | Standard | View | |||
| LEAP-005 NCT03797326 · Merck Sharp & Dohme LLC StandardView → | previously treated advanced solid tumors | Phase 2 | Standard | View | |||
| LEAP-006 NCT03829319 · Merck Sharp & Dohme LLC StandardView → | first-line metastatic nonsquamous non-small cell lung cancer | Phase 3 | Standard | View | |||
| PEMMELA NCT04287829 · The Netherlands Cancer Institute FocusedView → | second-line and third-line malignant pleural mesothelioma | Phase 2 | Focused | View | |||
| LEAP-007 NCT03829332 · Merck Sharp & Dohme LLC FocusedView → | PD-L1-positive treatment-naïve metastatic NSCLC | Phase 3 | Focused | View | |||
| KEYMAKER-U03 NCT04626518 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| SAMURAI NCT05327686 · NRG Oncology FocusedView → | metastatic unresected renal cell carcinoma | Phase 2 | Focused | View | |||
| CLEAR NCT02811861 · Eisai Inc. FocusedView → | first-line advanced renal cell carcinoma | Phase 3 | Focused | View | |||
| KEYMAKER-U03 NCT04626479 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced clear-cell renal cell carcinoma | Phase 1/Phase 2 | Focused | View | |||
| KEYNOTE-B61 NCT04704219 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced non-clear-cell renal cell carcinoma | Phase 2 | Focused | View | |||
| NCT05012371 NCT05012371 · M.D. Anderson Cancer Center FocusedView → | metastatic clear cell renal cell carcinoma | Phase 2 | Focused | View | |||
| KCSG HB23-04 NCT06138769 · Asan Medical Center FocusedView → | advanced hepatocellular carcinoma after first-line atezolizumab plus bevacizumab | Phase 2 | Focused | View | |||
| LEAP-008 NCT03976375 · Merck Sharp & Dohme LLC FocusedView → | metastatic NSCLC after platinum chemotherapy and immunotherapy | Phase 3 | Focused | View | |||
| NCT04393350 NCT04393350 · Emory University FocusedView → | locally advanced nonmetastatic clear cell renal cell carcinoma | Phase 2 | Focused | View | |||
| NCT05877820 NCT05877820 · RenJi Hospital FocusedView → | first-line advanced fumarate hydratase-deficient renal cell carcinoma | Phase 2 | Focused | View | |||
| GroundBBreaker 301 NCT07836530 · BeOne Medicines FocusedView → | Not given | Phase 3 | Focused | View | |||